| Literature DB >> 33416123 |
Yongsheng Jiang1, Rui Li1, Chunchan Han1, Lijiang Huang1.
Abstract
Recently, the increasing emergency of traffic accidents and the unsatisfactory outcome of surgical intervention are driving research to seek a novel technology to repair traumatic soft tissue injury. From this perspective, decellularized matrix grafts (ECM‑G) including natural ECM materials, and their prepared hydrogels and bioscaffolds, have emerged as possible alternatives for tissue engineering and regenerative medicine. Over the past decades, several physical and chemical decellularization methods have been used extensively to deal with different tissues/organs in an attempt to carefully remove cellular antigens while maintaining the non‑immunogenic ECM components. It is anticipated that when the decellularized biomaterials are seeded with cells in vitro or incorporated into irregularly shaped defects in vivo, they can provide the appropriate biomechanical and biochemical conditions for directing cell behavior and tissue remodeling. The aim of this review is to first summarize the characteristics of ECM‑G and describe their major decellularization methods from different sources, followed by analysis of how the bioactive factors and undesired residual cellular compositions influence the biologic function and host tissue response following implantation. Lastly, we also provide an overview of the in vivo application of ECM‑G in facilitating tissue repair and remodeling.Entities:
Keywords: extracellular matrix grafts; decellularization protocols; tissue engineering; the host response
Mesh:
Substances:
Year: 2020 PMID: 33416123 PMCID: PMC7797433 DOI: 10.3892/ijmm.2020.4818
Source DB: PubMed Journal: Int J Mol Med ISSN: 1107-3756 Impact factor: 4.101
Figure 1Schematic representation of ECM hydrogel from preparation to application. The native tissues can achieve a diversity of ECM hydrogels via combination of physical, chemical and biological approaches together. The prepared ECM hydrogels themselves with/without incorporating growth factors and/or stem cells are used for tissue repair and regeneration, including spinal cord injury, peripheral nerve injury and myocardial infarction. Some of these may become a primary option for remodeling a variety of clinical tissues defects.
Selected agents and techniques for decellularizing tissue.
| Methods/Refs. | Characteristics | Effects on ECM |
|---|---|---|
| Snap freezing ( | Decellularization of tendinous, ligamentous tissue and nerve tissue | Disruption of cellular membranes and inducing cell lysis |
| Mechanical sonication ( | Tissues with hard structures | Largely damage the ECM structure |
| Mechanical agitation ( | Removal of cellular contents | Direct damage to ECM |
| Triton X-100 ( | Removing nuclear and cytoplasmic waste | More effective cell removal from thin tissues |
| SDS ( | Applying for retaining the overall matrix structure | Removes nuclear remnants and cytoplasmic proteins |
| Sodium deoxycholate ( | Very effective for removing cellular remnants | Damages the matrix, similar to the SDS |
| CHAPS ( | Cell removal from thinner tissues, such as blood vessels and lung | Effectively removes cells in thin tissues and mildly disrupts ultrastructure in thin tissues |
| Trypsin ( | Specifically target ECM proteins | Digestion of the proteins in the ECM, in particular collagen laminin, and fibronectin |
| Pepsin ( | Generally target ECM proteins | Damage ECM proteins if digested too long |
| Lipase ( | Specifically targets lipids | Hydrolyzing fat to derive adipose derived ECM |
| Collagenases ( | Specifically targets collagen at early step | Effectively removes collagen in ECM; Prolonged expose will disrupt ECM ultrastructure |
| Nucleases ( | Specifically break down DNA or RNA sequences Highly efficiency | No function on ECM proteins; Only removal of nucleotides |
SDS, sodium dodecyl sulfate; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; GAGs, glycosaminoglycans.
Applications of different organ decellularization techniques to various organs.
| Organ | Decellularization agent | Solubilization protocol | Species | (Refs.) |
|---|---|---|---|---|
| Heart | 10 U/ml heparinized water | 10X PBS | Porcine | ( |
| Lung | 0.0035% Triton-X 100 | Perfusion | Rat | ( |
| Liver | 4% Triton X-100 | Voytik-Harbin | Rat | ( |
| Kidney | Gradient of SDS (0.5%-1.0%) | Perfusion | Rat | ( |
| Skin | 1% SDS and 0.5% pen/strep | Perfusion | Murine | ( |
| Nerve | 3.0% Triton X-100 | 0.01 M HCl | Porcine | ( |
| Skeletal muscle | 0.7% NaCl | Perfusion | Mouse | ( |
Perfusion involved i) Triton X-100 + SDS; ii) stir plate, RT, at least 48 h; iii) neutralized to pH 7.4 and physiological salt with NaOH and 10X PBS.